The following criteria is provided for health care professionals.

Inclusion Criteria:

• Performance status score of 0 or 1
• Measurable disease as per radiographic evaluation
• Disease-specific criteria for dose escalation:
  • Participants with any type of solid tumor for which no treatment is currently available, or
  • Participants with non-Hodgkin Lymphoma that has progressed on prior chemotherapy and unable to receive stem cell transplant or adoptive cell transfer
  • Participants may have received up to 5 prior anti-cancer therapies and an unlimited number of prior hormonal therapies.
• Disease-specific criteria for dose-expansion Cohort 1:
  • Participants with previously untreated locally advanced or metastatic NSCLC with a high PD-L1 expression
• Disease-specific criteria for dose-expansion Cohort 2:
  • Participants with metastatic melanoma with at least one prior anti-cancer therapy and progression after PD-L1 therapy
• Disease-specific criteria for dose-expansion Cohort 3:
  • Participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer with at least 1 prior chemotherapy and no prior PD-(L)1 therapy.
• Disease-specific criteria for dose-expansion Cohort 4:
  • Participants with metastatic cervical cancer with at least 1 prior chemotherapy and no prior PD-(L)1 therapy.
• Disease-specific criteria for dose-expansion Cohort 5:
  • Participants with diffuse large B-cell lymphoma (DLBCL) with at least 2 prior anti-cancer therapies and unable to receive stem cell transplant or adoptive cell transfer, or
  • Participants with multiple myeloma with at least 3 prior anti-cancer therapies and for whom no treatment is currently available.

Exclusion Criteria:

• History of trauma or major surgery within 28 days prior to the first dose of study treatment.
• Prior treatment with an anti-TIGIT antibody.
• Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
• Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.
• Discontinued prior immunotherapy for immune related adverse events with a high severity.

 

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply